MAPT and Alzheimer disease: Moreover, TA-3 treatment demonstrated the ability to reduce (phospho-)Tau in iPSC-derived neuronal cells of an AD patient, highlighting its potential as a Tau-specific degrader for therapeutic intervention in human AD.